Regulation of gene expression in prostate cancer cells with an artificially constructed promoter responsive to radiation

Gene Therapy

Volumn 19, Issue 2, 2012, Pages 219-227

  Morii, A ^a   Ogawa, R ^a   Watanabe, A ^a   Kakutani, S ^a   Zhao, Q L ^a   Kume, K ^b   Kondo, T ^a   Fuse, H ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b WAKASA WAN ENERGY RESEARCH CENTER   (Japan)

Author keywords

cis acting element; promoter; prostate cancer; radiation

Indexed keywords

DNA FRAGMENT; LUCIFERASE;

ARTICLE; CELL KILLING; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; TATA BOX; VIRUS RECOMBINANT; X IRRADIATION;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; LUCIFERASES; MALE; MICE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; TATA BOX; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; X-RAYS;

MUS MUSCULUS;

EID: 84856948388     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.89     Document Type: Article

References (29)

1. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM et al. Radical prostatectomy, external beam radiotherapyo72Gy, external beam radiotherapy X72Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stageT1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25-33. (Pubitemid 38010333)
2. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostate adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151: 640-645. (Pubitemid 24054701)
3. Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer 2004; 100: 1283-1292. (Pubitemid 38325958)
4. D'Ambrosio DJ, Pollack A, Harris EE, Price RA, Verhey LJ, Roach M et al. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 671-677. (Pubitemid 351199720)
5. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001; 51: 880-914.
6. Steiner MS, Gungrich JR. Gene therapy for prostate cancer: where are we now? J Urol 2000; 164: 1121-1136.
7. Eager R, Nemunaitis J. GM-CSF gene-transuded tumor vaccines. Mol Ther 2005; 12: 18-27.
8. Freytag S, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B et al. Five-year follow-up of trial of replication-component adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007; 15: 636-642.
9. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F et al. Suicide gene therapy with adenoviral delivery of HSV-TK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 2007; 15: 834-840. (Pubitemid 46432005)
10. MacRae EJ, Giannoudis A, Ryan R, Brown NJ, Hamdy FC, Maitland N et al. Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate 2006; 66: 470-494.
11. Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res 2003; 63: 7497-7506. (Pubitemid 37413494)
12. Marignol L, Robson T, McCarthy HO, Worthington J, Murray MM, Hollywood D et al. The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate? J Gene Med 2008; 10: 1032-1038.
13. Xing L, Sun X, Deng X, Kotedia K, Urano M, Koutcher JA et al. Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells. Radiother Oncol 2009; 92: 345-352.
14. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JW, Hanna NN et al. Spatial and temporal control of the gene therapy using ionizing radiation. Nat Med 1995; 1: 786-791.
15. Worthington J, Robson T, Murray M, O'Rourke M, Keilty G, Hirst DG. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Therapy 2000; 7: 1126-1131. (Pubitemid 30458804)
16. Scott SD, Joiner MC, Marples B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Therapy 2002; 9: 1396-1402. (Pubitemid 35244165)
17. Kagiya G, Ogawa R, Cook JA, Choudhuri R, DeGraff BG, Mitchell JB. Improvement and induction property of radiation-responsive promoter through DNA shuffling of 5¢-flanking regions of the human p21 gene. J Biosci Bioeng 2010; 110: 118-123.
18. Ogawa R, Sung-il L, Kagiya G, Hirano H, Fukuda S, Kondo T et al. Construction of X-rayinducible promoters thorough cis-acting element elongation and error-prone polymerase chain reaction. J Gene Med 2007; 10: 316-324.
19. Chendil D, Das A, Dey S, Mohiuddin M, Ahmed M. Par-4, a pro-apoptotic gene, inhibits radiation-induced NFkB activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 2002; 1: 152-160.
20. Meighan-Mantha RL, Riegel AT, Suy S, Harris V, Wang FH, Lozano C et al. Ionizing radiation stimulates octamer factor DNA binding activity in human carcinoma cells. Mol Cell Biochem 1999; 199: 209-215. (Pubitemid 29476159)
21. Burchardt M, Burchardt T, Shabsigh A, Ghafar M, Chen MW, Anastasiadis A et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCap prostate cancer cells. Prostate 2001; 48: 225-230. (Pubitemid 32816547)
22. Kagiya G, Ogawa R, Ito S, Fukuda S, Hatashita M, Tanaka Y et al. Identification of a cis-acting element responsive to ultrasound in the 5¢-flanking region of the human heme oxygenase-1 gene. Ultrasound Med Biol 2009; 35: 155-164.
23. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004; 23: 1599-1607. (Pubitemid 38406523)
24. Tyrrell RM, Applegate LA, Tromvoukis Y. The proximal promoter region of the human heme oxygenase gene contains elements involved in stimulation of transcriptional activity by a variety of agents including oxidants. Carcinogenesis 1993; 14: 761-765. (Pubitemid 23150016)
25. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Therapy 2000; 7: 511-517. (Pubitemid 30156566)
26. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822. (Pubitemid 32204573)
27. Kanai F, Kawakami T, Hamada H, Sudata A, Yoshida Y, Tanaka T et al. Adenovirusmediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-1951. (Pubitemid 28217471)
28. Sambrook J, Russell DW. Molecular Cloning: a Laboratory Manual, 3rd edn. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 2001.
29. Kagiya G, Ogawa R, Hatashita M, Takagi K, Kodaki T, Hiroishi S et al. Generation of a strong promoter for Escherichia coli from eukaryotic genome DNA. J Biotechnol 2005; 115: 239-248. (Pubitemid 41350389)